Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIP Safety, PK, and PD in PAH
NCT04791514Phase 2Terminated
- Sponsor
- Insmed Incorporated
- Start
- Mar 2022
- Primary completion
- Aug 2022
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treprostinil palmitil in pulmonary arterial hypertension (PAH), sponsored by Insmed Incorporated. Primary endpoint: Number of Participants Who Experience a Treatment Emergent Adverse Event up to 150 days. Started Mar 2022; status: terminated.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04791514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791514.